SAGA Diagnostics is stepping into the spotlight with Roche’s planned acquisition of the company for up to $595 million, a deal that underscores growing demand for ultra-sensitive cancer monitoring technologies. The startup has built its core around Pathlight, a tumor-informed molecular residual disease (MRD) platform that combines whole genome sequencing and digital PCR to track structural variants—an approach designed to detect cancer recurrence at very low levels. With the transaction expected to close by Q3 2026, SAGA’s platform will be integrated into Foundation Medicine, giving it access to global commercial infrastructure and accelerating its expansion beyond the U.S., where it is already used in early-stage breast cancer monitoring. The acquisition effectively shifts SAGA from a specialized innovator to a scaled player within Roche’s precision oncology stack, positioning its technology as a core component in next-generation cancer surveillance.
SAGA Diagnostics is a molecular diagnostics company focused on detecting and monitoring cancer through blood-based testing. The company develops tumor-informed molecular residual disease (MRD) assays designed to identify traces of cancer that remain after treatment or signal early recurrence. Its core platform, Pathlight, uses whole genome sequencing and digital PCR to track structural variants associated with an individual patient’s tumor. Headquartered in North Carolina’s Research Triangle Park, with additional operations in Lund, Sweden, SAGA works with pharmaceutical and biotechnology companies on clinical development programs across multiple cancer types, supporting both research and potential clinical applications in oncology monitoring.
“Our mission at SAGA is to intercept cancer early when patients are most treatable and curable,” said Roopom Banerjee, Executive Chairman of SAGA. “Foundation Medicine’s commercial scale and innovation accelerates our ability to bring this unique MRD platform to more patients worldwide. We are proud of our team for advancing innovation in the MRD field and commercially launching Pathlight to improve patient outcomes.”
Foundation Medicine is a U.S.-based molecular diagnostics company focused on cancer profiling and disease monitoring. The company develops genomic tests that analyze tumor tissue and blood samples to identify mutations, alterations, and biomarkers that may inform treatment decisions and track disease progression. Its portfolio includes tissue-based and liquid biopsy assays used in clinical and research settings, as well as tools for longitudinal monitoring of cancer through circulating tumor DNA. An independent affiliate of Roche, Foundation Medicine also works with pharmaceutical companies and research institutions, using genomic data and analytics to support drug development and expand the use of precision medicine in oncology.
“Pathlight strengthens our comprehensive portfolio of diagnostic solutions and reinforces our commitment to transforming cancer care throughout a patient’s experience,” said Dan Malarek, CEO of Foundation Medicine. “MRD is one of the fastest-growing areas within diagnostics and this technology provides us with a clinically available ultra-sensitive offering. Pathlight has demonstrated strong clinical performance in breast and colorectal cancer, and we look forward to expanding its applicability across other tumor types and indications to improve the lives of even more patients.”
Pathlight’s MRD platform will strengthen Foundation Medicine’s portfolio of high-quality diagnostic tests and solutions that support treatment selection, and the monitoring of both treatment response and disease recurrence. Foundation Medicine also plans to leverage Roche’s AXELIOS sequencing platform and the Digital LightCycler® PCR platform to develop a decentralized MRD solution which will enable patient access in healthcare settings worldwide.
Pathlight uses a proprietary combination of whole genome sequencing (WGS) and digital PCR to identify and track large-scale genomic changes known as structural variants (SVs). By optimizing for SVs, Pathlight enables ultra-sensitive MRD detection. Pathlight is covered by Medicare for cancer recurrence monitoring in early-stage breast cancer across all subtypes. It is currently available for patients within the United States, with plans for international launch.
Pathlight will expand Foundation Medicine’s monitoring portfolio, which includes FoundationOne®Monitor and Foundation Medicine’s tissue-informed whole genome sequencing molecular residual disease test (Tissue-Informed WGS MRD) available for research use. FoundationOne Monitor is a circulating tumor DNA (ctDNA) monitoring test which uses a blood sample to support healthcare providers with clarity on their patient’s response to treatment and inform next steps in care. The Tissue-Informed WGS MRD test monitors hundreds to thousands of tumor-specific short variants, enabling accurate quantification of ctDNA in patients with cancer for a more complete picture after treatment.
Click here to read more IPO/M&A news.
Read the orginal article: https://arcticstartup.com/saga-diagnostics-acquired-by-foundation-medicine-roche/
